PubRank

Kimberly L Blackwell

Author PubWeight™ 42.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008 4.45
2 Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009 3.79
3 Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 3.62
4 Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005 2.77
5 Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010 1.98
6 Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003 1.83
7 Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer 2008 1.59
8 Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2010 1.55
9 Erythropoietin biology in cancer. Clin Cancer Res 2006 1.48
10 Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 2008 1.43
11 Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 2011 1.17
12 Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007 1.11
13 Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data. Int J Hyperthermia 2010 1.08
14 Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006 1.00
15 Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. PLoS One 2009 1.00
16 Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila) 2013 0.99
17 Safety of bevacizumab in patients with metastatic breast cancer. Oncology 2011 0.98
18 DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. Int J Hyperthermia 2009 0.96
19 Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther 2011 0.96
20 Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 2011 0.96
21 Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 2011 0.93
22 Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. Cancer Chemother Pharmacol 2008 0.92
23 A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 2012 0.88
24 New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest 2011 0.86
25 Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia 2014 0.84
26 Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. Support Care Cancer 2014 0.83
27 Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010 0.80
28 The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 2006 0.78
29 Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival. Int J Hyperthermia 2015 0.78
30 The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. Breast 2008 0.76
31 How can we optimize treatment of HER2-positive metastatic breast cancer? Oncology (Williston Park) 2013 0.75
32 The significance of distant metastases in breast cancer. Breast 2008 0.75